English
CD38 / BCMA / Firefly Luciferase CHO Recombinant Cell Line
CD38 / BCMA / Firefly Luciferase CHO Recombinant Cell Line
Artikelnummer
BPS78148
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: 1. Useful for validation of anti-CD38 and anti-BCMA bispecific antibody.
2. Useful as CD38- and/or BCMA-expressing target cells in co-culture assay with CD38- and/or BCMA-CAR-T cells, for both CD38/BCMA-specific cell killing assay and cytokine production assay.
Background: The CD38 protein is a dimeric, non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes the second messengers cyclic ADP-ribose and NADP. CD38 is highly expressed by lymphoid and myeloid cells, particularly plasma cells. Increased CD38 expression on chronic lymphocytic leukemia (CLL) cells is linked to aggressive disease features and poor clinical outcome. CD38 is used as a prognostic marker for patients with CLL and multiple myeloma (MM), and is an ideal target for immunotherapy in CLL and MM.
B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy, not only because of its restricted expression in nonmalignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein (also known as ADPRC1, Genbank accession #NM_001775) and human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD38 and BCMA was confirmed by flow cytometry.
Host Cell Line: CHO
Mycoplasma Testing: The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: 2 vials of frozen cells. 2 x 10^6 cells in 1 ml of 10% DMSO
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
Applications: 1. Useful for validation of anti-CD38 and anti-BCMA bispecific antibody.
2. Useful as CD38- and/or BCMA-expressing target cells in co-culture assay with CD38- and/or BCMA-CAR-T cells, for both CD38/BCMA-specific cell killing assay and cytokine production assay.
Background: The CD38 protein is a dimeric, non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes the second messengers cyclic ADP-ribose and NADP. CD38 is highly expressed by lymphoid and myeloid cells, particularly plasma cells. Increased CD38 expression on chronic lymphocytic leukemia (CLL) cells is linked to aggressive disease features and poor clinical outcome. CD38 is used as a prognostic marker for patients with CLL and multiple myeloma (MM), and is an ideal target for immunotherapy in CLL and MM.
B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy, not only because of its restricted expression in nonmalignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein (also known as ADPRC1, Genbank accession #NM_001775) and human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD38 and BCMA was confirmed by flow cytometry.
Host Cell Line: CHO
Mycoplasma Testing: The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
Storage Stability: Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: 2 vials of frozen cells. 2 x 10^6 cells in 1 ml of 10% DMSO
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
| Artikelnummer | BPS78148 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 78148 |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Hamster |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
